A phase I clinical trial to evaluate the safety and biological activity of HIV-IT (TAF) (HIV-1IIIBenv-transduced, autologous fibroblasts) in asymptomatic HIV-1 infected subjects

Hum Gene Ther. 1994 Aug;5(8):997-1017. doi: 10.1089/hum.1994.5.8-997.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I

MeSH terms

  • Adult
  • Clinical Protocols*
  • Eligibility Determination
  • Female
  • Fibroblasts / transplantation*
  • Follow-Up Studies
  • Gene Products, env / administration & dosage
  • Gene Products, env / genetics*
  • Gene Products, env / immunology*
  • Gene Transfer Techniques
  • Genetic Therapy
  • HIV Infections / immunology
  • HIV Infections / therapy*
  • HIV-1*
  • Humans
  • Immunization, Secondary
  • Immunotherapy
  • Male
  • Risk Factors
  • Safety
  • T-Lymphocytes, Cytotoxic / immunology

Substances

  • Gene Products, env